CervoMed releases corporate presentation highlighting neflamapimod Phase 2b efficacy signal in dementia with Lewy bodies

CervoMed Inc.

CervoMed Inc.

CRVO

0.00
  • CervoMed highlighted Phase 2b data in dementia with Lewy bodies showing DP Batch B met exposure targets with clinically meaningful efficacy.
  • CDR-SB improved versus placebo at 16 weeks, with a -1.12 difference in the planned Phase 3 population excluding AD co-pathology.
  • Over 32 weeks, DP Batch B showed a -1.20 CDR-SB difference versus DP Batch A, described as an 89% reduction in decline.
  • Progression risk fell with DP Batch B versus placebo, hazard ratio 0.49; versus DP Batch A, hazard ratio 0.46.
  • Phase 3 planning calls for a single 32-week trial in about 300 patients using pTau181 under 21 pg/mL, with 50 mg TID dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.